NVS

Expect a Bustling Week for IPOs

Nine initial public offerings are expected to hit the market this week, including deals in the biotech and REIT spaces. More 

How to Play Today’s All-Too-Familiar Market

Like a year ago, the bulls are snorting wildly ... and the dumb money is buying while smart money sells. It's safe to assume that a solid correction is coming. More 

Dead Cat Bounce Likely in the S&P

Yesterday the S&P made its biggest drop of 201--and the biggest gainers were some of the biggest losers. My theory is that we're looking at a dead cat bounce. More 

Novartis Won’t Pay Outgoing Chairman $78M

Novartis has dropped plans to give outgoing Chairman Daniel Vasella a six-year non-compete deal valued at $78 million after a public outcry over the amount. More 

4 Pharmaceutical Stocks to Buy Now

This week, four Pharmaceutical stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy"). More 

Flu’s Pain Is All Gain for These Companies

As this year's flu season intensifies, so do the profits for some businesses such as vaccine makers, pharmacies and even certain food and beverage makers. More 

Novartis Chairman Steps Down, Shares Jump

Daniel Vasella announced that he is stepping down as chairman of Novartis and will be replaced by Bayer executive Joerg Reinhardt. More